Simply Oncology Podcast Por John McGrane & Michael Rowe arte de portada

Simply Oncology

Simply Oncology

De: John McGrane & Michael Rowe
Escúchala gratis

Acerca de esta escucha

Welcome to Simply Oncology.
Cancer is daunting for both patients and for clinical teams.
Dr John McGrane and Dr Michael Rowe are oncologists who want to break down the complex parts of cancer care into clear and simple sessions.
We will dive deep into the world of cancer research, patient stories and the latest cancer breakthroughs.
Simply Oncology will have patient focused episodes along with episodes that allow anyone with an interest in oncology to stay up to date.

We hope you join us as we unpick all parts of cancer.

John & Mike

© 2025 Simply Oncology Enfermedades Físicas Hygiene & Healthy Living
Episodios
  • Episode 52: Discussing Peri-operative trials in Bladder Cancer with Professor Alison Birtle

    Episode 52: Discussing Peri-operative trials in Bladder Cancer with Professor Alison Birtle
    May 29 2025

    Send us a text

    🚨May is Bladder Cancer Awareness Month

    🎙️What better way to mark this than a Simply Oncology Podcast - Bladder Cancer episode with the irrepressible Professor Alison Birtle. Alison is an internationally recognised expert in bladder and prostate cancer - and is a Simply Oncology Friend of the Show.

    🎙️We discuss the recent peri-operative trials such as NIAGARA
    🎙️What do surgical adjuvant and neoadjuvant trails now mean for the bladder cancer pathway?
    Más Menos
    27 m
  • Episode 51: Cancer of Unknown Primary with Dr Natalie Cook

    Episode 51: Cancer of Unknown Primary with Dr Natalie Cook
    May 20 2025

    Send us a text
    Más Menos
    34 m
  • Episode 49: In the Clinic - Erdafitinib & Enfortumab Vedotin in metastatic urothelial cancer with Professor Rob Jones

    Episode 49: In the Clinic - Erdafitinib & Enfortumab Vedotin in metastatic urothelial cancer with Professor Rob Jones
    May 9 2025

    Send us a text

    Part 2 of our discussion on bladder cancer with Professor Rob Jones.

    We have new drug classes in Bladder cancer !!

    We look at Erdafitinib which is coming in the post Immunotherapy space to NHS England.

    We also look ahead to Antibody Drug Conjugates - in particular Enfortumab Vedotin - with EV 302 trial results and what access to this means for the UK bladder community.

    These are exciting times and we discuss potential side effects of these classes of drugs and how we intend to use them.

    Enjoy
    Más Menos
    22 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones